Document is current
Any future updates will be listed below
-
Authors
Strzelczyk, Adam https://orcid.org/0000-0001-6288-9915
Schubert-Bast, Susanne https://orcid.org/0000-0003-1545-7364
-
Funding
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Accepted: 9 January 2022
First Online: 14 February 2022
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. Medical writing assistance was funded by GW Pharma (Germany) GmbH.
: A. Strzelczyk reports personal fees and grants from Angelini Pharma/Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, Marinus Pharmaceuticals, UCB Pharma, UNEEG medical, and Zogenix. S. Schubert-Bast reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals, LivaNova, UCB Pharma, and Zogenix.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors reviewed the literature, drafted the manuscript, generated the figures, and assume full responsibility for the final publication.
